Lantern Pharma Q1 net loss $4.1M; cash $65.2M, RADR platform tops 20B data points

Lantern Pharma Inc.

Cash and marketable securities $65.2M at March 31, 2022 vs $70.7M at Dec 31, 2021; net cash used $5.3M in Q1.
Net loss $4.1M ($0.38/share) vs $2.5M ($0.24) in Q1 2021; R&D expenses rose to $2.7M from $1.3M.
RADR AI platform surpassed 20 billion data points; on track for 25 billion by year-end 2022.
IND for LP-184 targeted for Q3 2022; HARMONIC Phase 2 trial for LP-300 expected to start enrollment summer 2022.
Share repurchase program extended; $3.6M remaining authorized through July 31, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.